TRINETRA › Sectors › Healthcare
Max Healthcare Institute Limited (MAXHEALTH) — share price, P/E and fundamentals
Max Healthcare Institute Limited (NSE: MAXHEALTH) closed at ₹860.00 on 30 Oct 2026, -28.5% over one year, against a 52-week range of ₹797.00 – ₹1,221.90.
In the quarter ended 30 Sept 2026 (consolidated, filed 30 Oct 2026) it reported revenue of ₹2,569 cr and net profit of ₹415 cr, a 16.2% net margin; revenue grew 20.3% and profit grew 21.3% year on year.
On four consecutive filed quarters its trailing P/E is 60.6; since 20 May 2025 its own P/E has ranged from 54.1 to 117.6 (median 86.2), and today's reading is higher than 4% of those 358 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 14.7%, ROCE 15.2%, debt-to-equity 0.33, Piotroski F-score 7 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 59% of 63 sector peers; PBT margin higher than 60% of 63 sector peers; ROE higher than 52% of 63 sector peers.
Key figures
| Last close | ₹860.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -17.8% / -13.9% / -28.5% |
| 52-week low – high | ₹797.00 – ₹1,221.90 |
| Market capitalisation | ₹83,705 cr |
| Trailing P/E | 60.6 |
| Price / book | 7.39 |
| EV / EBITDA | 33.7 |
| Earnings yield | 1.7% |
| TTM EPS | ₹14.18 |
| TTM net profit | ₹1,381 cr |
| Quarter revenue | ₹2,569 cr |
| Quarter net profit | ₹415 cr |
| Net margin | 16.2% |
| Revenue growth (YoY) | +20.3% |
| Profit growth (YoY) | +21.3% |
| Return on equity | 14.7% |
| ROCE | 15.2% |
| Debt / equity | 0.33 |
| Current ratio | 0.84 |
| Free cash flow | ₹406 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹196.7 cr |
Against Healthcare peers
| Metric | MAXHEALTH | Peer median | Percentile |
|---|---|---|---|
| Net margin | 16.15 | 12.67 | 59 |
| PBT margin | 21.05 | 17.57 | 60 |
| ROE | 14.65 | 13.87 | 52 |
| ROCE | 15.15 | 17.26 | 38 |
| Debt / equity | 0.33 | 0.11 | 75 |
| FCF margin | 8.22 | -0.87 | 60 |
| Cash conversion | 1.35 | 1.25 | 58 |
| Trailing P/E | 60.63 | 43.07 | 71 |
Questions
What is the P/E ratio of Max Healthcare Institute Limited?
Max Healthcare Institute Limited's trailing P/E is 60.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 20 May 2025 its P/E has ranged 54.1–117.6.
What were Max Healthcare Institute Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Max Healthcare Institute Limited reported revenue of ₹2,569 cr and net profit of ₹415 cr (consolidated), filed with the exchange on 30 Oct 2026.
What is Max Healthcare Institute Limited's ROE?
Return on equity is 14.7% based on the balance sheet dated 30 Sept 2026.
Does Max Healthcare Institute Limited have debt?
Debt-to-equity is 0.33 on the balance sheet dated 30 Sept 2026.
What is MAXHEALTH's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, MAXHEALTH traded between ₹797.00 and ₹1,221.90.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Glenmark Pharmaceuticals Limited (GLENMARK)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.